BEA 2180 BR

Drug Profile

BEA 2180 BR

Alternative Names: BEA-2180; BEA-2180-BR

Latest Information Update: 10 Nov 2014

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Antibronchitics; Bronchodilators
  • Mechanism of Action Cholinergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Chronic obstructive pulmonary disease

Most Recent Events

  • 05 Dec 2013 No development reported - Phase-II for Chronic obstructive pulmonary disease in USA, Belgium, Netherlands, Canada, Germany, Hungary, South Korea, Mexico, Poland, Russia, Spain and Taiwan (Inhalation)
  • 09 Mar 2013 Adverse events and efficacy data from a phase II trial in Chronic obstructive pulmonary disease released by Boehringer Ingelheim
  • 31 May 2009 Boehringer Ingelheim completes a phase II trial in Chronic obstructive pulmonary disease in USA, Canada, Germany, Hungary, South Korea, Mexico, Poland, Russia, Spain and Taiwain (NCT00528996)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top